 |
|
|
| |
ELBASVIR/GRAZOPREVIR PLUS SOFOSBUVIR ± RIBAVIRIN IN TREATMENT-NAIVE AND TREATMENT-EXPERIENCED PATIENTS WITH HEPATITIS C VIRUS GENOTYPE 3 INFECTION AND COMPENSATED CIRRHOSIS: THE C-ISLE STUDY
|
| |
| |
Reported by Jules Levin
AASLD 2016 Nov 11-15 Boston, MA
Mark Sulkowski,1 Curtis Cooper,2 Jean-Michel Molina,3 Susanna Naggie,4 K.C. Huang,5 Anu Osinusi,5 Luisa M. Stamm,5 Benedetta Massetto,5 John McNally,5 Diana M. Brainard,5 John G. McHutchison,5 David Wyles,6 Jurgen K. Rockstroh,7 Douglas Dieterich8
1Johns Hopkins Hospital, Baltimore, MD; 2University of Ottawa, Ontario, Canada; 3Hopital Saint-Louis, Université Paris-Sorbonne, Paris, France; 4Duke University Medical Center, Durham, NC;
5Gilead Sciences, Inc., Foster City, CA; 6UC San Diego School of Medicine, La Jolla, CA; 7Universität Bonn, Germany; 8Icahn School of Medicine at Mount Sinai, New York, NY
Reported by Jules Levin
AASLD 2016 Nov 11-15 Boston, MA
Graham R. Foster*, Kosh Agarwal, Matthew Cramp, Sulleman Moreea, Stephen Barclay, Jane Collier, Ashley S. Brown, Stephen D. Ryder, Andrew Ustianowski, Daniel M. Forton, Ray Fox, Fiona Gordon, William M. Rosenberg, David J. Mutimer, Jiejun Du, Christopher L. Gilbert, Ernest Asante-Appiah, Janice Wahl, Eliav Barr, Barbara Haber
*Queen Mary University, London, United Kingdom
|
| |
|
|
|
|
|
